apl. Prof. Dr. Stefan Krause

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology

Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancer (2026) Sandherr M, Schalk E, Heinz WJ, Köhler P, Krause S, Liss B, Kausche L, et al. Journal article PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype (2026) Stasik S, Eckardt JN, Röllig C, Baldus CD, Serve H, Müller-Tidow C, Schäfer-Eckart K, et al. Journal article Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy (2026) Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH, Alakel N, et al. Journal article TriCAM (NCT02976558) – a randomized controlled pilot study of complementary medicine in allogeneic stem cell transplantation to improve quality of life (2025) Behzad A, Krause S, Mackensen A, Müller F, Stark A, Völkl S, Rösler W Journal article Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients (2025) Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, et al. Journal article One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy (2025) Scholz JK, Stabel L, Schwingen NR, Knopf J, Flatt AS, Bäuerle T, Krause S, et al. Journal article, Medical case study Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia (2025) Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, et al. Journal article Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial (2025) Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Müller LP, Schmid C, Krause S, et al. Journal article Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis (2025) Ronnacker J, Muller PJ, Mikesch JH, Zukunft S, Weinbergerová B, Šrámek J, Valka J, et al. Journal article VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML (2025) Kretschmer L, Ruhnke L, Schliemann C, Fransecky L, Steffen B, Kaufmann M, Burchert A, et al. Journal article